Effect Of Adalimumab Treatment On İnflammatory And Hematological Parameters İn Patients With Hidradenitis Suppurativa

Hidradenitis suppurativa (HS), a chronic inflammatory disease that typically manifests after puberty, is characterized by painful nodules, abscesses, draining sinus tracts, and scars in areas rich in apocrine glands such as the axillary and inguinal regions. In recent years, blood-based biomarkers such as the Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), Monocyte/Lymphocyte Ratio (MLR), Mean Platelet Volume (MPV), Systemic Immune-Inflammation Index (SII), and Pan-Immune-Inflammation Value (PIV) have been used as significant indicators of systemic inflammation. While there are few studies evaluating these biomarkers in HS, the response of these markers to treatment has only been assessed in one study to date. Our study aims to investigate the effect of adalimumab treatment on blood-based systemic inflammation biomarkers in HS, where inflammation plays a significant role. The study included 42 adult patients who received adalimumab treatment at our dermatology and venereology clinic between January 2020 and January 2023. Medical records for complete blood count results of the patients were retrospectively reviewed. All systemic inflammation-based biomarkers were calculated from the absolute values of the complete blood count. The SII was calculated with the following formula: (neutrophil count x platelet count/lymphocyte count). The PIV was calculated as follows: (neutrophil count x platelet count x monocyte count/lymphocyte count). Values before the treatment and at the 12th week of treatment were compared. When the changes in the inflammatory parameters of the patients were examined, it was found that NLR (2,13 ± 0,87 vs 2,26 ± 1,12), PLR (111,01 ± 39,89 vs 99,43 ± 35,34), MLR (0,27 ± 0,11 vs 0,28 ± 0,12), MPV (9,59 ± 0,71 vs 9,70 ± 0,79), SII (680,79 ± 330,18 vs 687,89 ± 442,66) and PIV (552,02 ± 330,71 vs 605,05 ± 415,96) values did not change statistically significantly after treatment (p > 0.05). While there was a significant decrease in platelet count compared to before treatment, no statistically significant difference was found in the other evaluated blood cells. Adalimumab treatment has not had a significant effect on systemic inflammation markers in HS, an inflammatory disease. More studies are needed to evaluate the effect of adalimumab on these markers in HS.